Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1973 1
1978 1
1980 1
1987 1
1990 1
1991 1
1992 1
1994 1
1995 1
1996 1
1997 3
1998 2
1999 7
2000 1
2001 1
2002 2
2003 6
2004 8
2005 1
2006 5
2007 6
2008 3
2009 5
2010 9
2011 6
2012 10
2013 8
2014 4
2015 2
2016 7
2017 5
2018 4
2019 6
2020 10
2021 4
2022 5
2023 7
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

138 results

Results by year

Filters applied: . Clear all
Page 1
Friedreich ataxia: clinical features and new developments.
Keita M, McIntyre K, Rodden LN, Schadt K, Lynch DR. Keita M, et al. Neurodegener Dis Manag. 2022 Oct;12(5):267-283. doi: 10.2217/nmt-2022-0011. Epub 2022 Jun 29. Neurodegener Dis Manag. 2022. PMID: 35766110 Free PMC article. Review.
Friedreich's ataxia (FRDA), a neurodegenerative disease characterized by ataxia and other neurological features, affects 1 in 50,000-100,000 individuals in the USA. ...Finally, new perspectives on the neuroanatomy of FRDA and its developmental features will r
Friedreich's ataxia (FRDA), a neurodegenerative disease characterized by ataxia and other neurological features, affect
Omaveloxolone: First Approval.
Lee A. Lee A. Drugs. 2023 Jun;83(8):725-729. doi: 10.1007/s40265-023-01874-9. Drugs. 2023. PMID: 37155124 Review.
Omaveloxolone (SKYCLARYS) is an orally active, small molecule semi-synthetic triterpenoid drug that increases antioxidant activity, which is being developed by Reata Pharmaceuticals, Inc. for the treatment of Friedreich's ataxia. In patients with Friedreich's …
Omaveloxolone (SKYCLARYS) is an orally active, small molecule semi-synthetic triterpenoid drug that increases antioxidant activity, which is …
Emerging therapies in Friedreich's Ataxia.
Zesiewicz TA, Hancock J, Ghanekar SD, Kuo SH, Dohse CA, Vega J. Zesiewicz TA, et al. Expert Rev Neurother. 2020 Dec;20(12):1215-1228. doi: 10.1080/14737175.2020.1821654. Epub 2020 Sep 21. Expert Rev Neurother. 2020. PMID: 32909841 Free PMC article. Review.
INTRODUCTION: Friedreich's ataxia (FRDA) is a progressive, neurodegenerative disease that results in gait and limb ataxia, diabetes, cardiac hypertrophy, and scoliosis. ...AREAS COVERED: Areas covered include past and emerging therapies for FRDA, including an …
INTRODUCTION: Friedreich's ataxia (FRDA) is a progressive, neurodegenerative disease that results in gait and limb ataxia
The global epidemiology of hereditary ataxia and spastic paraplegia: a systematic review of prevalence studies.
Ruano L, Melo C, Silva MC, Coutinho P. Ruano L, et al. Neuroepidemiology. 2014;42(3):174-83. doi: 10.1159/000358801. Epub 2014 Mar 5. Neuroepidemiology. 2014. PMID: 24603320 Free article. Review.
The prevalence range of dominant HCA was 0.0-5.6/10(5), with an average of 2.7/10(5) (1.5-4.0/10(5)). Spinocerebellar ataxia type 3 (SCA3)/Machado-Joseph disease was the most common dominant ataxia, followed by SCA2 and SCA6. The autosomal recessive (AR) HCA …
The prevalence range of dominant HCA was 0.0-5.6/10(5), with an average of 2.7/10(5) (1.5-4.0/10(5)). Spinocerebellar ataxia t …
Ferroptosis and NRF2: an emerging battlefield in the neurodegeneration of Alzheimer's disease.
Lane DJR, Metselaar B, Greenough M, Bush AI, Ayton SJ. Lane DJR, et al. Essays Biochem. 2021 Dec 22;65(7):925-940. doi: 10.1042/EBC20210017. Essays Biochem. 2021. PMID: 34623415 Review.
., Alzheimer's, Parkinson's and Huntington's diseases, Motor neuron disease, Friedreich ataxia (FRDA)). Ferroptotic death results from lethal levels of phospholipid hydroperoxides that are generated by iron-dependent peroxidation of polyunsaturated fatty acids (PUFA …
., Alzheimer's, Parkinson's and Huntington's diseases, Motor neuron disease, Friedreich ataxia (FRDA)). Ferroptotic death resu …
Efficacy of echocardiography for differential diagnosis of left ventricular hypertrophy: special focus on speckle-tracking longitudinal strain.
Tanaka H. Tanaka H. J Echocardiogr. 2021 Jun;19(2):71-79. doi: 10.1007/s12574-020-00508-3. Epub 2021 Jan 18. J Echocardiogr. 2021. PMID: 33460030 Free PMC article. Review.
It is commonly detected in athletes, arterial hypertension, aortic stenosis, hypertrophic cardiomyopathy, cardiac amyloidosis, Fabry disease, or Friedreich's ataxia. Echocardiography plays an important role in detecting LVH and underlying causes in current clinical …
It is commonly detected in athletes, arterial hypertension, aortic stenosis, hypertrophic cardiomyopathy, cardiac amyloidosis, Fabry disease …
Trinucleotide repeat disorders.
Den Dunnen WFA. Den Dunnen WFA. Handb Clin Neurol. 2017;145:383-391. doi: 10.1016/B978-0-12-802395-2.00027-4. Handb Clin Neurol. 2017. PMID: 28987184 Review.
This group can be divided into CAG- versus non-CAG-repeat diseases. Apart from spinocerebellar ataxia type 6 and 12 (SCA6 and SCA12), these CAG-repeat diseases, as well as Huntington disease-like 2 (HDL2) and SCA8, can be neuropathologically identified using 1C2 pol …
This group can be divided into CAG- versus non-CAG-repeat diseases. Apart from spinocerebellar ataxia type 6 and 12 (SCA6 and SCA12), …
Genetic Infiltrative Cardiomyopathies.
Sweet ME, Mestroni L, Taylor MRG. Sweet ME, et al. Heart Fail Clin. 2018 Apr;14(2):215-224. doi: 10.1016/j.hfc.2017.12.003. Heart Fail Clin. 2018. PMID: 29525649 Free PMC article. Review.
Hereditary ataxias: overview.
Jayadev S, Bird TD. Jayadev S, et al. Genet Med. 2013 Sep;15(9):673-83. doi: 10.1038/gim.2013.28. Epub 2013 Mar 28. Genet Med. 2013. PMID: 23538602 Free article. Review.
There are more than 35 autosomal dominant types frequently termed spinocerebellar ataxia and typically having adult onset. The most common subtypes are spinocerebellar ataxia 1, 2, 3, 6, and 7, all of which are nucleotide repeat expansion disorders. Autosomal …
There are more than 35 autosomal dominant types frequently termed spinocerebellar ataxia and typically having adult onset. The most c …
Spinocerebellar degeneration.
Perlman SL. Perlman SL. Expert Opin Pharmacother. 2003 Oct;4(10):1637-41. doi: 10.1517/14656566.4.10.1637. Expert Opin Pharmacother. 2003. PMID: 14521474 Review.
In the past 25 years, there have been, at most, 18 controlled (Class 1) trials for ataxia, which have focused on neurotransmitter mechanisms. There is currently only one National Institute of Neurological Disorders and Stroke-sponsored drug trial for ataxia (Phase I …
In the past 25 years, there have been, at most, 18 controlled (Class 1) trials for ataxia, which have focused on neurotransmitter mec …
138 results